KR20220125370A - Cosmetic compositions - Google Patents

Abstract

The present invention is Echinacea purpurea extract, Silybum marianum extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) Disclosed are compositions and methods of using the same for treating pruritus comprising one or more combinations of mixtures comprising sterols.

Description

Cosmetic compositions {COSMETIC COMPOSITIONS}

This application claims priority to U.S. Provisional Patent Application No. 61/784,564, filed March 14, 2013, and U.S. Provisional Patent Application No. 61/816,286, filed April 26, 2013. The contents of the referenced application are incorporated herein by reference.

The present invention relates generally to compositions and methods useful for treating skin conditions. More specifically, the present invention is Echinacea purpurea ( Echinacea purpurea ) extract, Silybum marianum ( Silybum ) marianum ) extract, glycerin, and topical skin care compositions comprising a mixture comprising cetylhydroxyproline palmitamide/stearic acid/ Brassica campestris (rapeseed) sterol and such A method of treating pruritic, dry, or erythemic skin with the compositions.

Pruritus or itch is defined as an unpleasant sensation in the skin that causes the urge to scratch. It can be localized or generalized and can occur as an acute or chronic condition. Itching can be intractable and prevent normal living, as well as a diagnostic and therapeutic challenge. The root cause of this sensation is the activity of nerve fibers in the epidermis and upper layers of the dermis. For example, dry skin can activate these nerve fibers, which can lead to an itchy skin feeling that usually leads to scratching. However, scratching can be associated with skin irritation or erythema, pre-existing skin conditions (eg, seborrhoeic dermatitis, atopic eczema, contact dermatitis, or xerotic eczema). such as dry skin), and overall unsightly or visually unpleasant appearance of the skin. Dry skin can also cause fine lines and wrinkles.

Compositions for resolving pruritus symptoms are known. However, these compositions do not treat both itchy skin and the treatment of the cause of itchy skin.

The following references are expressly incorporated herein by reference to the extent that they provide exemplary procedural or other detailed additions to supplement this specification. US Patent 2,798,053 US Patent 3,755,560 US Patent 4,421,769 US Patent 4,509,949 US Patent 4,599,379 US Patent 4,628,078 US Patent 4,835,206 US Patent 4,849,484 US Patent 5,011,681 US Patent 5,087,445 US Patent 5,100,660 US Patent 5,411,744 US Patent 6,203,802 US Patent 6,387,398 US public number. 2004/0109905 US public number. 2005/0163880

Cao et al., Free Radical Biol Med. 14(3): 303-311, 1993 International Cosmetic Ingredient Dictionary and Handbook, 12th Edition, (“CTFA”), Volume 1:918-19. 1050-61, 12, 80; 2008. Kreuter, 1998 McCutcheon’s, 1986

The inventors have discovered a combination of ingredients that can be used in topical skin formulations as antipruritic agents while also treating the underlying cause of itchy/itchy skin (eg dry skin). In this sense, the combination can be said to have a dual effect: (1) treatment of pruritic skin; and (2) treating the cause of itchy skin, which may be dry skin. The advantage of this dual effect is that only one composition is needed to effectively treat and prevent pruritic and dry skin. "Dry skin" or "xeroderma" refers to skin with reduced moisture (compared to normal skin) that can cause itchy skin, skin with flakes ("flaky skin"). skin"), and includes skin with scales ("scaly skin"), or skin with cracks. Examples of dry skin include seborrheic dermatitis, atopic eczema, contact dermatitis, or dry eczema.

In one embodiment, the present invention is Echinacea purpurea extract, Silybum marianum ) extract, glycerin, and / or cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (rapeseed) Disclosed is a composition comprising a mixture comprising sterols. In another embodiment, the present invention provides a topical skin care composition comprising a dermatologically acceptable vehicle and a combination of the following ingredients: Echinacea purpurea extract, Silybum marianum extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (rapeseed) discloses a mixture comprising sterols. In another embodiment, the composition activates human cannabinoid receptor type 2 in the skin, and/or inhibits fatty acid amide hydrolase activity.

The Echinacea Purpuria ( Echinacea purpurea ) extract and/or Silybum marianum extract may be an aqueous, alcoholic, hydro-alcoholic, or oil-based extract. In another embodiment, the Echinacea purpurea extract is an aqueous extract. In another embodiment the Silybum marianum extract is an aqueous extract. The Echinacea purpurea extract and / or Silybum marianum ( Silybum ) marianum ) extract may be from whole plants, leaves, seeds, flowers, stems, or roots. In another embodiment, the Echinacea purpurea ) extract from the whole plant. In another embodiment, the Silybum marianum ) extract is from the fruit.

The composition may further comprise humectants, UV absorbers, antioxidants, structurants, emulsifiers, silicone containing compounds, essential oils, thickeners, and/or preservatives such as those disclosed throughout this specification. The composition may include pharmaceutical ingredients such as those disclosed throughout this specification. The composition comprises 0.0001 to 10% by weight (or 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, ,7, 8, 9, or 10% by weight or more) of Echinacea purpurea ) extract, 0.0001 to 10% by weight of Silybum marianum extract (or 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, ,7, 8, 9, or 10% by weight) or more), 0.0001 to 10% by weight of glycerin (or 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, ,7, 8, 9, or 10% by weight or more), and/or 0.0001 to 10% by weight of cetylhydroxyproline palmitamide / steric acid / Brassica campestris (Rapeseed) mixtures comprising sterols (or 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, ,7, 8, 9, or 10% by weight or more). In another embodiment, the composition comprises about 0.50 weight percent Echinacea purpurea extract, about 1.0 weight percent Silybum marianum extract, and about 2.0 weight percent cetylhydroxyproline arm. Mitamide/Steric Acid/ Brassica campestris campestris ) (Rapeseed) contains mixtures containing sterols. In another embodiment, the composition comprises 15% by weight of glycerin.

The present invention also discloses a method of treating pruritus comprising topically applying to the skin in need of treatment any one of the compositions disclosed throughout this specification, wherein topical application to the skin in need of treatment is provided. treats pruritus Pruritus, or pruritus, is defined as an unpleasant sensation that causes the urge to scratch. It can be associated with a number of diseases, including but not limited to dry skin and erythematous skin. In addition to treating pruritus, the composition can also treat dry skin at the same time. In another embodiment, the present invention discloses a method of reducing symptoms associated with pruritus comprising topically applying to skin in need thereof any one of the compositions disclosed herein, wherein the composition Their topical application reduces symptoms associated with pruritus. In another embodiment, the compositions of the present invention may be used to treat fine lines and wrinkles by topically applying the compositions to fine lines and/or wrinkles.

In certain aspects, the composition is applied to the skin and at least 5, 10, 15, 30, or more minutes, or 1, 4, 8, 12, 16, 20, or Remains for 24 hours. The composition may be applied to pruritic skin, erythematous skin or dry skin or seborrheic dermatitis present on facial skin, leg skin, ankle skin, arm skin, hand skin, and/or scalp skin.

In addition, the present invention is (a) Echinacea furpuria ( Echinacea purpurea extract and Silybum marianum ) extract, wherein the combination of extracts activates human cannabinoid receptor type 2 in the skin and inhibits fatty acid amide hydrolase activity; and (b) glycerin and cetylhydroxyproline palmitamide/steric acid/ Brassica campestris campestris ) (Rapeseed) a mixture comprising sterols (wherein glycerin and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ) (Rapeseed) discloses a method for treating or reducing symptoms of pruritus comprising topically applying a composition comprising a mixture comprising a sterol to the pruritic skin) .

The compositions of the present invention may be formulated into topical skin care compositions. The compositions may be cosmetic compositions. In another aspect, the compositions may be included in a cosmetic vehicle. Non-limiting examples of cosmetic vehicles are disclosed in other sections of this specification and are known to those skilled in the art. Examples of cosmetic vehicles are emulsions (eg, oil-in-water and water-in-oil emulsions), creams, lotions, solutions (eg, aqueous or hydro-alcoholic solutions). ), anhydrous bases (eg, lipsticks or powders), gels, and ointments. In certain aspects, the compositions may be formulated as a cream, gel, or lotion. In another embodiment, the composition is an emulsion (eg, oil-in-water, water-in-oil, hydrophilic-in-hydrophobic, hydrophobic-in-hydrophobic, silicone-in-water ), water-in-silicone, etc.).

The compositions may also be formulated for topical skin application at least 1, 2, 3, 4, 5, 6, 7, or more times per day during use. In another aspect of the invention, the compositions may be storage stable or color stable, or both. It is also contemplated that the viscosity of the composition may be selected to achieve a desired result (eg, depending on the type of composition desired, the viscosity of such a composition may range from about 1 cps to well over a million cps, or any range. or an integer derivable therein (e.g. 2 cps, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, 90000, 100000, 200000, 300000, 400000, 500000, 600000, 700000, 800000, 900000, 1000000 cps, etc., measured on a Brookfield Viscometer using a TC spindle at 25°C, 2.5 rpm). may have a pH of from about 6 to about 9. In other aspects, the pH may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14. The compositions of the present invention can have UVA and UVB absorption properties.The compositions are 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more, or any integer or derived therein, a Sun Protection Factor (SPF).The compositions can be sunscreen lotions, sprays, or creams. In certain aspects, the compositions can be oil-free, substantially anhydrous, and/or anhydrous. Another aspect includes compositions with water.

Compositions of the present invention may also include any one, any combination, or all of the following additional ingredients: water, chelating agent, humectant, preservative, thickener, silicone containing compound, essence cell oil, structure topical, vitamin, pharmaceutical ingredient, antioxidant, or any combination or mixture of these ingredients. In certain aspects, the composition may comprise at least two, three, four, five, six, seven, eight, nine, ten, or all of these additional ingredients as defined in the preceding sentence. Non-limiting examples of these components are identified throughout this specification and are incorporated by reference in this section. The amount of these components ranges from 0.0001% to 99.9% by weight or volume of the composition; or any integer or range between those disclosed in other sections of this specification, which are incorporated by reference in this paragraph.

In addition, the compositions can be used to treat or prevent a variety of as well as other skin conditions. For example, the compositions can be used to treat or prevent fine lines or wrinkles, erythema, sensitive skin, or inflamed skin. In certain aspects, erythema, sensitive skin, or inflamed skin is caused by skin sunburn, electrical treatment of the skin, skin burns, contact allergies, systemic allergies, skin toxicity, exercise, worms It is caused by stings, bacterial infection, viral infection, fungal infection, protozoa infection, massage, or windburn. In another aspect, the following additional skin conditions may be treated or prevented according to the compositions and methods disclosed herein and throughout the claims: pruritus, lentigo, spider veins, age spots ( age spots, senile purpura, keratosis, melasma, blotches, nodules, sun damaged skin, dermatitis (seborrheic dermatitis, nummular dermatitis) ), contact dermatitis, atopic dermatitis, exfoliative dermatitis, perioral dermatitis, and stasis dermatitis), psoriasis, folliculitis Folliculitis, rosacea, acne, impetigo, erysipelas, erythrasma, eczema, and other infectious skin conditions. In certain non-limiting aspects, the skin condition is UV light, aging, irradiation, chronic sun exposure, environmental pollution, air pollution, wind, cold, heat, chemicals, disease pathologies, smoking , or exposure to malnutrition. The skin may be facial skin or non-facial skin (eg, arms, legs, hands, chest, back, feet, etc.). The method may further comprise identifying a person in need of skin treatment. The person may be male or female. A person's age is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 , 80, 85, 90, 95 years old, or older, or any range derivable therein. The method also includes administering an effective amount: to increase the turnover of the stratum corneum of the skin; to increase collagen synthesis in fibroblasts; To increase cellular antioxidant defense mechanisms (e.g., exogenous additions of antioxidants reduce or prevent oxidative damage to skin, cells, proteins, and lipids in skin cells (e.g., keratin enhance, enhance, or prevent loss of cellular antioxidants such as catalase and glutathione in cells (keratinocytes, melanocytes, Langerhans cells, etc.); to inhibit melanogenesis in melanocytes; topical application to reduce or prevent oxidative damage to the skin (including reducing the amount of lipid peroxides and/or protein oxidation in the skin).

Also contemplated are kits comprising any one of the compositions disclosed herein and throughout the claims. In certain embodiments, the composition is contained in a container. The container may be a bottle, a dispenser, or a package. The container may provide a predetermined amount of the composition. In certain aspects, the compositions are provided as a spray, dollop, or liquid. The container may include an indicia on its surface. The indication may be a letter, an abbreviation, a picture, or a symbol.

Also contemplated are products comprising the compositions of the present invention. In a non-limiting aspect, the product may be a cosmetic product. The cosmetic products may be those described in other sections of this specification or those known to those skilled in the art. Non-limiting examples of products include moisturizers, creams, lotions, skin softeners, foundations, night creams, lipsticks, cleansers, toners, sunscreens, masks, or anti-aging products. .

In addition, Examples 1 to 33 of the present invention are disclosed below. Example 1 Echinacea purpuria ( Echinacea purpurea ) extract, Silybum Marianum ( Silybum ) marianum ) extract, glycerin, and an effective amount of a mixture comprising cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( rapeseed ) sterol is topically applied to the skin in need thereof. A method of treating pruritus comprising topical application, wherein topical application of the composition treats pruritus. Example 2 is the method of Example 1, wherein the composition activates human cannabinoid receptor type 2 in the skin and inhibits fatty acid amide hydrolase activity. Example 3 according to Example 1 or 2, Echinacea purpurea ) extract is an aqueous extract. Example 4 according to any one of Examples 1 to 3, wherein the Echinacea purpurea ) extract is a method that is from the whole plant. Example 5 is the method according to any one of Examples 1 to 4, wherein the Silybum marianum extract is an aqueous extract. Example 6 is the method according to any one of Examples 1 to 5, wherein the Silybum marianum ) extract is from the fruit. Example 7 is the method of any one of Examples 1 to 6, wherein the composition is formulated as a cream, lotion, emulsion, serum or cleanser. Example 8 is the method of any one of Examples 1-7, wherein the composition is an oil to in to water emulsion or a water to in to oil emulsion. Example 9 is the method according to any one of Examples 1 to 8, wherein the effective amount is Echinacea purpurea extract 0.001 to 10% by weight, Silybum marianum extract 0.001 to 10% by weight, and Cetylhydroxyproline palmitamide / steric acid / Brassica campestris campestris ) (Rapeseed) 0.001 to 10% by weight of a mixture containing sterol. Example 10 is the method of Example 9, wherein the effective amount is 0.50% by weight of Echinacea purpurea extract, 1.0% by weight of Silybum marianum extract, and cetylhydroxyproline palmitamide/s Tersan/Brassica campestris ( Brassica campestris ) (Rapeseed) 2.0 wt% of a mixture containing sterols. Example 11 is the method of Example 10, wherein the effective amount is 15% by weight of glycerin. Example 12 is the method of any one of Examples 1-9, wherein the skin is itchy skin, dry skin, or erythematous skin. Example 13 is the method of any one of Examples 1-12, wherein the composition is applied to the skin and remains on the skin for at least 5 minutes after topical application. Example 14 is the method of any one of Examples 1-13, wherein the skin in need of treatment is facial skin, leg skin, ankle skin, arm skin, hand skin, or scalp skin. Example 15 is the method of any one of Examples 1-14, wherein the composition further comprises at least one of a moisturizer, a UV absorber, an antioxidant, a structurant, an emulsifier, a silicone containing compound, an essential oil, a thickener, and a preservative. to be. Example 16 is the method of any one of Examples 1-15, wherein the composition further comprises a pharmaceutical ingredient. Example 17 Echinacea purpurea ) extract, Silybum marianum extract, and an effective amount of a mixture comprising cetylhydroxyproline palmitamide / steric acid / Brassica campestris (rapeseed) sterol A method of reducing symptoms associated with pruritus comprising topically applying to skin in need thereof, wherein topical application of said composition reduces symptoms associated with pruritus. Example 18 is an extract of Echinacea purpurea , and Silybum marianum ) extract (wherein the combination of extracts activates human cannabanoid receptor type 2 and inhibits fatty acid amide hydrolase activity in the pruritic skin) and glycerin and cetylhydroxyproline palmitamide/steric acid/ Brassica campestris campestris ) (Rapeseed) a mixture comprising sterols (wherein said glycerin and cetylhydroxyproline palmitamide/steric acid/Brassica campestris ( Brassica ) campestris ) (Rapeseed) The combination of a mixture containing a sterol is a method comprising topically applying a composition comprising the pruritus skin to the pruritus skin). Example 19 is a dermatologically acceptable vehicle and Echinacea purpurea extract, Silybum marianum ) extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) A topical skin care composition comprising a combination comprising a mixture comprising a sterol. Example 20 is the method of Example 19, wherein the Echinacea purpurea ) extract is a topical skin care composition that is an aqueous extract. Example 21 is the method of Example 19 or 20, wherein the Echinacea purpurea ) extract is a topical skin care composition from the whole plant. Embodiment 22 is the method according to any one of embodiments 19-21, wherein the Silybum marianum ) extract is a topical skin care composition that is an aqueous extract. Example 23 is the method of any one of Examples 19-22, wherein the Silybum marianum ) extract from the fruit It is a topical skin care composition. Example 24 is the topical composition of any one of Examples 19-23, wherein the composition further comprises at least one of a moisturizer, a UV absorber, an antioxidant, a structurant, an emulsifier, a silicone containing compound, an essential oil, a thickener, and a preservative. It is a skin care composition. Example 25 is the topical skin care composition of any one of Examples 19-24, wherein the composition further comprises a pharmaceutical ingredient. Example 26 is the topical skin care composition of any one of Examples 19-25, wherein the composition is formulated as a cream, lotion, gel, or serum. Example 27 is the topical skin care composition of any one of Examples 19-26, wherein the composition is an oil to in to water emulsion or a water to in to oil emulsion. Example 28 is the topical skin care composition of any one of Examples 19-27, wherein the composition comprises 0.001 to 10% by weight of each component or combination of components. Example 29 is the method of Example 28, wherein the effective amount is Echinacea purpurea ) extract 0.50% by weight, Silybum marianum ) extract 1.0% by weight, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) 2.0 wt% of a mixture containing sterols. Example 30 is the method of Example 29, wherein the effective amount is 15% by weight of glycerin. Example 31 is the topical skin care composition of any one of Examples 19-28, wherein the composition activates human cannabinoid receptor type 2 in the skin. Example 32 is the topical skin care composition of any one of Examples 19-31, wherein the composition inhibits fatty acid amide hydrolase activity in the skin. Example 33 is the topical skin care composition of any one of Examples 19-28, wherein the composition activates human cannabinoid receptor type 2 in the skin and inhibits fatty acid amide hydrolase activity.

The compositions and methods for using them may “comprise,” “consist essentially of,” or “consist of” any one of the ingredients disclosed throughout this specification. can As used in this specification or claim(s), the words "comprising" (and any of the words "comprising", such as "comprise" and "comprises") form), "having" (and any form of having, such as "have" and "has"), "including" (and "includes)" )" and any form of including, such as "include," or "containing" (and such as "contains" and "contain"). Any form of containing) is neither inclusive nor open-ended, nor does it exclude additional, unrecited components or method steps.

"Consisting essentially of" means that the inclusion of additional ingredients in the composition substantially affects and beneficial properties of the composition as an antipruritic agent and composition for the treatment of dry, keratinous, or cracked skin. means it doesn't For example, if the composition is Echinacea purpurea extract, Silybum marianum ) extract, glycerin, and two, three, or all four of a mixture comprising cetylhydroxyproline palmitamide/steric acid/ Brassica campestris (rapeseed) sterol, any combination, any If "consisting primarily of" one of, the composition excludes any ingredients that may materially affect the beneficial properties of the compositions for treating itchy skin or dry, keratinous, or chapped skin. For example, ingredients that may irritate the skin, cause dryness of the skin, or cause an itchy sensation in the skin would be excluded.

It is contemplated that any embodiment discussed herein may be practiced for any method or composition of the invention, and vice versa. In addition, the compositions of the present invention can be used to achieve the methods of the present invention.

In one embodiment, the compositions of the present invention may be excellent for pharmaceutical or cosmetic purposes. "Pharmaceutically elegant" and/or "cosmetically elegant" describes a composition that has certain tactile properties that feel pleasant on the skin (e.g. compositions that are not too thin or oily, compositions having a silky texture, non-greasy or non-sticky compositions, etc.). Pharmaceutically or cosmetically superior may also relate to the creamy or lubricating properties of the composition or to the water retention properties of the composition.

By “topical application” is meant the application or spread of a composition onto the surface of keratinous tissue. "Topic skin compositions" include compositions suitable for topical application over keratinous tissue. Such compositions are generally dermatologically acceptable without undue toxicity, incompatibility, instability, allergic reactions, and the like when applied to the skin. The topical skin care compositions of the present invention may have a viscosity selected to avoid significant dripping or pooling after application to the skin.

"Keratinous tissue" includes keratin-containing layers disposed as the outermost protective covering of a mammal and includes, but is not limited to, skin, hair and nails.

The terms “about” or “approximately” are defined to be close enough to be understood by one of ordinary skill in the art, and in one non-limiting embodiment the terms are within 10%, preferably within 5%, more preferably within 10%. preferably within 1%, and/or most preferably within 0.5%.

The term “substantially” and variations thereof are defined as predominantly, but not necessarily entirely, specified as understood by one of ordinary skill in the art, and in one non-limiting embodiment substantially within 10%, within 5%, within 1%. , or within 0.5%.

The terms “inhibiting,” “reducing,” “treating,” or any variation of these terms, when used herein and/or in the claims, refer to any measurable reduction or desired Including complete inhibition to achieve results.

As used herein and/or in the claims, the term “effective” means sufficient to achieve a desired, expected, or intended result.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and examples, while indicating specific embodiments of the invention, are given by way of example only. It is also contemplated that changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from the detailed description of the present invention.

The itchy sensation is usually limited to the area of the skin and adjacent mucosa. However, scratching can be associated with skin irritation or erythema, pre-existing skin conditions (eg, seborrhoeic dermatitis, atopic eczema, contact dermatitis, or xerotic eczema). such as dry skin), and overall unsightly or visually unpleasant appearance of the skin. Dry skin can also lead to fine lines and wrinkles.

The root cause of this sensation is the activity of nerve fibers in the epidermis and upper layers of the dermis. For example, dry skin can activate these nerve fibers, which can lead to an itchy skin feeling usually followed by scratching. Cannabinoid receptors type 1 (CBr1) and type 2 (CBr2) are located in the epidermis. The CBr2 receptor is a G protein-coupled receptor encoded by the CNR2 gene. Some cannabinoid agonists can potentially suppress histamine-induced itchiness in the skin. In addition, topical agonists of cannabinoid receptors may have antipruritic effects in atopic eczema and uremic pruritus.

Instead of using different compositions to treat itchy skin and dry skin, the inventors have discovered a specific combination of ingredients that can be incorporated into a topical composition to treat both skin conditions simultaneously. As previously discussed, this combination is associated with Echinacea purpurea ) extract, Silybum marianum extract, glycerin, and / or cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) contains combinations of mixtures containing sterols. Echinacea Purpuria purpurea ) extract was found to bind to human cannabinoid receptor type 2 in vitro , which activates CBr2, and Silybum marianum ) extract was found to inhibit fatty acid amide hydrolase (FAAH) activity. FAAH is known to destroy cannabinoids, which in turn activates CBr2. The inventors have found that the combination of these extracts works in a synergistic manner to increase and maintain CBr2 activity, which can reduce the sensation of itchy or itchy skin.

These and other non-limiting aspects of the invention are set forth in the specification below.

A. Active Ingredients

Echinacea purpurea is a flowering plant native to North America. The extract may be obtained from whole plants, roots, flowers, stems, leaves, flowers/leaf/stems, or leaves/roots. Such extracts are commercially available from a wide variety of sources (see, eg, International Cosmetic Ingredient Dictionary and Handbook, 12 ^th Edition, 2008 (“CTFA”), Volume 1, pages 918-19, incorporated by reference). In a specific example, the whole plant extract is used (see page 918 of CTFA). In another embodiment, the lettuce extract is an aqueous extract. The present inventors have found that these extracts can bind to the CBR2 receptor in human skin.

Silybum Marianum marianum ) (Thistle), this is a plant native to Eastern Europe and Asia. It is known to produce red to violet flowers, glossy pale green leaves with white veins, and fruits. Silybum of the present invention marianum ) extract is hydroalcoholic containing silymarin as an active ingredient (silymarin is a mixture of flavanonol derivatives including silybin, silycristine, silydianin, isosolibine, isosilycristine) (water and denatured alcohol) extract. The fruit part of Silybum marianum contains silymarin. The Silybum marianum extract chills the fruit pulp from the fruit part of this plant, and then injects the pulp into a hydroalcoholic solution of water and SD alcohol 39-C (alcohol denaturation.) to obtain an extract. can be obtained by The extract may then be filtered and packaged for storage or added to the composition of the present invention. In addition to this extraction process, Silybum marianum ) extract can be purchased from Provital SA (SPAIN) under the trade names PRONALEN SILYMARIN HSC or PRONALEN SILYMARIN SPE. In another embodiment, the extract is an aqueous extract. The extract can be used to treat an inflammatory reaction caused to the skin by, for example, dry skin.

Returning to glycerin, it is a polyhydric alcohol with the following chemical structure:

It is commercially available from a wide variety of sources (see, eg, International Cosmetic Ingredient Dictionary and Handbook, 12 ^th Edition, 2008 (“CTFA”), Volume 1, pages 1050-61, incorporated by reference). Glycerin is a known skin moisturizer.

Cetyl hydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica campestris ) For mixtures comprising (rapeseed) sterols, such mixtures are commercially available from Symrise (Germany) under the trade name SymRepair. SymRepair products include hexyldecanol, bisabolol, stearic acid, cetylhydroxyproline palmitamide, and Brassica campestris ) (rapeseed) is a combination of sterols.

Furthermore, as mentioned above, the compositions of the present invention may also include rosmarinic acid-α-D-glucoside. This compound forms an ester between rosmaric acid and glucose. It has the following chemical structure:

It is commercially available from LibraGen (Toulouse, France) under the trade name Rosmarinyl™ Glucoside. This ingredient can be used to treat an inflammatory reaction caused to the skin by, for example, dry skin.

In addition to the commercial availability of the extracts identified above, the extracts can be produced by obtaining the corresponding plant or a portion thereof to produce an extract by extraction methods known to those skilled in the art. For example, one of ordinary skill in the art would be able to isolate any one of the extracts identified above from the corresponding plant part or whole plant using any known method suitable in the art. In one non-limiting embodiment, the plant (or any part of the plant) may be crushed by mechanical means resulting in a puree. The puree is then treated to be substantially free of impurities or unwanted solids. The puree is then poured into a shallow container and quickly cooled to a low temperature, eg, quick frozen, eg -20°C. or lower temperature, preferably under vacuum to remove moisture content (lyophilization). The resulting extract can then be used in the compositions of the present invention.

In another aspect, aqueous, alcoholic, aqueous-alcoholic, or oily extraction techniques, or combinations thereof, can be used on the whole plant or any part thereof to produce an extract. In this process, the desired part of the plant or the whole plant is ground (eg, blender) and then injected into the desired solvent to obtain the desired extract (eg, water, alcohol, water/alcohol, or oily solvents) ). The extract may then be stored in liquid form, lyophilized, or subjected to further processing techniques (eg, heating, cooling, etc.). Extraction processes are well known to those skilled in the art of extraction (eg, maceration, infusion, percolation, digestion, decoction, high temperature continuous Hot continuous extraction, aqueous-alcoholic extract, counter current extract, microwave assisted extraction, ultrasonic extraction, supercritical fluid extraction fluid extracts, phytonic extracts (eg, with hydro-fluoro-carbon solvents), and the like.

B. Compositions of the Invention

It is contemplated that the compositions of the present invention may include any of the active ingredients described herein or any combination thereof. In certain aspects, the active ingredients may be combined (e.g., Echinacea purpurea extract, Silybum marianum ) extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) mixtures containing sterols). The composition may include any number of combinations of the additional ingredients described throughout this specification. The concentration of any component in the compositions may vary. In a non-limiting embodiment, for example, a composition of the present invention comprises, for example, at least about 0.0001%, 0.0002%, 0.0003%, 0.0004%, 0.0005% of at least one or more ingredients recited throughout the specification and claims. , 0.0006%, 0.0007%, 0.0008%, 0.0009%, 0.0010%, 0.0011%, 0.0012%, 0.0013%, 0.0014%, 0.0015%, 0.0016%, 0.0017%, 0.0018%, 0.0019%, 0.0020%, 0.0021%, 0.0022 %, 0.0023%, 0.0024%, 0.0025%, 0.0026%, 0.0027%, 0.0028%, 0.0029%, 0.0030%, 0.0031%, 0.0032%, 0.0033%, 0.0034%, 0.0035%, 0.0036%, 0.0037%, 0.0038%, 0.0039%, 0.0040%, 0.0041%, 0.0042%, 0.0043%, 0.0044%, 0.0045%, 0.0046%, 0.0047%, 0.0048%, 0.0049%, 0.0050%, 0.0051%, 0.0052%, 0.0053%, 0.0054%, 0.0055% , 0.0056%, 0.0057%, 0.0058%, 0.0059%, 0.0060%, 0.0061%, 0.0062%, 0.0063%, 0.0064%, 0.0065%, 0.0066%, 0.0067%, 0.0068%, 0.0069%, 0.0070%, 0.0071%, 0.0072 %, 0.0073%, 0.0074%, 0.0075%, 0.0076%, 0.0077%, 0.0078%, 0.0079%, 0.0080%, 0.0081%, 0.0082%, 0.0083%, 0.0084%, 0.0085%, 0.0086%, 0.0087%, 0.0088%, 0.0089%, 0.0090%, 0.0091%, 0.0092%, 0.0093%, 0.0094%, 0.0095%, 0.0096%, 0.0097%, 0.0098%, 0.0099%, 0.0100%, 0.0200%, 0.0250%, 0.0275%, 0.0300%, 0.0325%, 0.0350%, 0.0375%, 0.0400%, 0.0425%, 0.0450%, 0.0475%, 0.0500%, 0.0525%, 0.0550%, 0.0575%, 0.0600%, 0.0625%, 0.0650%, 0.0675% , 0.0700%, 0.0725%, 0.0750%, 0.0775%, 0.0800%, 0.0825%, 0.0850%, 0.0875%, 0.0900%, 0.0925%, 0.0950%, 0.0975%, 0.1000%, 0.1250%, 0.1500%, 0.1750%, 0.2000 %, 0.2250%, 0.2500%, 0.2750%, 0.3000%, 0.3250%, 0.3500%, 0.3750%, 0.4000%, 0.4250%, 0.4500%, 0.4750%, 0.5000%, 0.5250%, 0.0550%, 0.5750%, 0.6000%, 0.6250%, 0.6500%, 0.6750%, 0.7000%, 0.7250%, 0.7500%, 0.7750%, 0.8000%, 0.8250%, 0.8500%, 0.8750%, 0.9000%, 0.9250%, 0.9500%, 0.9750%, 1.0%, 1.1% , 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8 %, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1% , 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8 %, 7 .9%, 8.0%, 8.1%, 8.2%, 8.3%, 8.4%, 8.5%, 8.6%, 8.7%, 8.8%, 8.9%, 9.0%, 9.1%, 9.2%, 9.3%, 9.4%, 9.5 %, 9.6%, 9.7%, 9.8%, 9.9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75% , 80%, 85%, 90%, 95%, or 99% or any range derivable therein in their final form, constituting essentially of, or consisting of. In a non-limiting aspect, the percentage can be calculated by weight or volume of the total composition. One of ordinary skill in the art will appreciate that concentrations may vary with addition, substitution, and/or subtraction of components in a given composition.

The compositions disclosed herein may also include various antioxidants to retard oxidation of one or more components. In addition, prevention of the action of microorganisms may include preservatives such as various antibacterial and antifungal agents including, but not limited to, parabens (eg, methylparaben, propylparaben), chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof. can be caused by In another embodiment, the composition is free of parabens.

C. vehicle ( Vehicles )

The compositions of the present invention can be incorporated into all types of vehicles. Non-limiting examples of suitable vehicles include emulsions (eg, water-in-oil, water-in-oil-in-water, oil-in-water, water-in-water). silicone-in-water, water-in-silicone, oil-in-water-in-oil, oil-in-water-in-silicone emulsion) , creams, lotions, solutions (both aqueous and hydroalcoholic), dry bases (such as lipsticks or powders), gels, and ointments or any other method as described above or forgoing as known to those skilled in the art. (Remington's, 1990). Modifications and other suitable vehicles will be apparent to those skilled in the art and are suitable for use in the present invention. In certain aspects, the combinations and concentrations of the compounds, ingredients, and chemicals are selected in such a way that the combinations are chemically compatible and do not form complexes which precipitate from the finished product. It is important to be

Also, Echinacea purpurea extract, Silybum marianum extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) ingredients identified throughout this specification, including, but not limited to, a mixture comprising a sterol, or any combination thereof, individually or in combination for delivery to a target area such as the skin It is contemplated that they may be (combinatorially) encapsulated. Non-limiting examples of encapsulation techniques include encapsulating liposomes, vehicles, and/or nanoparticles (eg, encapsulating the ingredients into which they are trapped) that can be used as delivery vehicles capable of delivering the ingredients to the skin. includes the use of biodegradable and non-biodegradable colloidal particles - examples including nanospheres and nanocapsules - containing biodegradable and/or absorbed polymeric materials (see, e.g., U.S. Patents 6,387,398; US Pat. No. 6,203,802; US Pat. No. 5,411,744; Kreuter 1998).

D. Cosmetic products and regulations of manufacture ( Articles )

The composition of the present invention may also be used in sunscreen products, indoor skin tanning products, hair products, finger nail products, moisturizing creams, skin benefit creams and lotions, softeners, day lotions, gels, ointments, It can be used in many cosmetic products including, but not limited to, foundation, night cream, lipstick, cleanser, toner, mask, or other known cosmetic products or application. Furthermore, the cosmetic products may be formulated as leave-on or rinse-off products. In certain aspects, the compositions of the present invention are stand-alone products.

E. Additional Ingredients

Echinacea Purpuria purpurea extract, Silybum marianum extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) A mixture comprising sterols, as well as the ingredients disclosed throughout this specification, the compositions of the present invention may include additional ingredients such as cosmetic ingredients and pharmaceutically active ingredients. Non-limiting examples of these additional ingredients are set forth in the specification below.

1. Cosmetic Ingredients

The CTFA International Cosmetic Ingredient Dictionary and Handbook (2004 and 2008) describes a wide range of non-limiting cosmetic ingredients that can be used in the context of the present invention. Examples of these ingredient classes include: fragrances (artificial and natural), dyes and color ingredients (eg Blue 1, Blue 1 Lake, Red 40, titanium dioxide, D&C blue no. 4, D&C green no. 5, D&C orange no. 4, D&C red no. 17, D&C red no. 33, D&C violet no. 2, D&C yellow no. 10), and D&C yellow no. 11), adsorbents, lubricants, solvents, humectants (e.g., emollients that affect the skin's natural moisturizing mechanism), humectants, film formers, occlusive agents ), and agents), water-repellants, UV absorbers (physical and chemical absorbers such as paraaminobenzoic acid (“PABA”) and corresponding PABA derivatives, titanium dioxide, zinc oxide, etc.) , essential oils, vitamins (eg, A, B, C, D, E, and K), trace metals (eg, zinc, calcium and selenium), anti-irritants ( For example, steroidal and non-steroidal anti-inflammatory agents), botanical extracts (e.g., aloe vera, chamomile, cucumber extract, ginkgo biloba, ginseng, and rosemary), antibacterial agents, antioxidants (e.g. BHT and tocopherol), chelating reagents (eg disodium EDTA and tetrasodium EDTA), preservatives (eg methylparaben and propyleneparaben), pH adjusters (eg sodium hydroxide and citric acid), Adsorbents (e.g., aluminum starch octenylsuccinate, kaolin, cornstarch, oat starch, cyclodextrin, talc, and zeolite), skin bleaching and skin lightening agents (e.g., hydroquinone and niacinamide lactate), humectants (e.g., sorbitol, urea, and mannitol), exfoliants ), waterproofing agents (e.g. magnesium/aluminum hydroxide), skin conditioning agents (e.g. cotton, aloe extract, allantoin, bisabolol, ceramide, dimethicone, hyaluronic acid, and dipotassium glycyrrhizate). Some non-limiting examples of these ingredients are provided in the specification below.

a. UV absorbent

UV absorbers that may be used in combination with the compositions of the present invention include chemical and physical sunblocks. Non-limiting examples of chemical sunscreens that may be used include paraaminobenzoic acid (PABA), PABA esters (glyceryl PABA, amyldimethyl PABA, and octyldimethyl PABA), butyl PABA, ethyl PABA, ethyldihydroxy Propyl PABA, benzophenones (oxybenzone, sulisobenzone, benzophenone, and benzophenone-1 through 12), cinnamates (octyl methoxycinnamate, iso Amyl p-methoxycinnamate, octylmethoxy cinnamate, cinoxate, diisopropyl methyl cinnamate, DEA-methoxycinnamate ), ethyl diisopropylcinnamate, glyceryl octanoate dimethoxycinnamate and ethyl methoxycinnamate, cinnamate esters, salicylates ) (homomethyl salicylate, benzyl salicylate, glycol salicylate, isopropylbenzyl salicylate, etc.), anthranilates, ethyl urocanate ), homosalate, octisalate, dibenzoylmethane derivatives (eg, avobenzone), octocrylene, octyl triazone ), digalloy trioleate ( digalloy trioleate), glyceryl aminobenzoate, dihydroxyacetone and lawson, ethylhexyl triazone, dioxyl butamido triazone, benzylidene Malonate polysiloxane, terephthalylidene dicamphor sulfonic acid, disodium phenyl dibenzimidazole tetrasulfonate, diethylamino hydroxybenzoate hexyl hydroxybenzoyl hexyl benzoate, bis diethylamino hydroxybenzoyl benzoate, bis benzoxazolylphenyl ethylhexylimino triazine, drometrizole trisiloxane Bis-benzotriazolyl tetramethylbutyl phenol (methylene bis-benzotriazolyl tetramethylbutyiphenol), and bis-ethylhexyloxyphenol methoxyphenyltriazine, 4-methylbenzylidenecamphor, and iso pentyl 4-methoxycinnamate. Non-limiting examples of physical sunblocks include kaolin, mica, petrolatum and metal oxides (eg, titanium dioxide and zinc oxide).

b. moisturizer

Non-limiting examples of humectants that may be used with the compositions of the present invention include amino acids, chondroitin sulfate, diglycerin, erythritol, fructose, glucose, glycerin, glycerol polymer, glycol, 1,2,6- Hexanetriol, honey, hyaluronic acid, hydrogenated honey, hydrogenated starch hydrolysate, inositol, lactitol, maltitol, maltose, mannitol, natural moisturizing factor , PEG-15 butanediol, polyglyceryl sorbitol, salts of pyrrolidone carboxylic acid, potassium PCA, propylene glycol, sodium glucuronate, sodium PCA, sorbitol, sucrose, tre trehalose, urea, and xylitol.

Other examples are acetylated lanolin, acetylated lanolin alcohol, alanine, algae extract, aloe barbadensis ( aloe ). barbadensis ), aloe-barbadensis ( aloe-barbadensis ) extract, aloe barbadensis ( aloe barbadensis ) gel, alcia officinalis ( althea ) officinalis ) extract, apricot ( Prunus armeniaca ) armeniaca ) kernel oil, arginine, arginine aspartate, arnica montana extract, aspartic acid, avocado ( persea gratissima ) oil, sphingo barrier sphingolipids, butyl alcohol, beeswax, behenyl alcohol, beta-sitosterol, birch ( betula alba ) bark extract, borage (borigo officinalis) Cinalis ( borago officinalis ) extract, butcherbroom ruscus aculeatus extract, butylene glycol, calendula officinalis extract, calendula officinalis ( calendula ) officinalis oil, candelilla ( euphorbia cerifera )) wax, canola oil, caprylic/capric triglycerides, cardamon ( elettaria cardamomum ) oil, carnauba ( copernicia cerifera ) )) wax, carrots ( Daucus carota sativa) carota sativa ) oil, castor ( ricinus communus ) communis )) oil, ceramide, ceresin, ceteareth-5, ceteareth-12, ceteareth-20, cetearyl octanoate, ceteth-20, Ceteth -24, cetyl acetate, cetyl octanoate, cetyl palmitate, chamomile (Anthemis nobilis ) oil, cholesterol, cholesterol esters, cholesterol hydroxystearate, citric acid, clary (Salvia Scalea ) sclarea ) oil, cocoa ( theobroma cacao) cacao ) butter, cococaprylate/caprate, coconut ( cocos nucifera )) oil, collagen, collagen amino acids, corn ( zea mays) mays )) oil, fatty acids, decyl oleate, dimethicone copolyol, dimethiconol, dioctyl adipate, dioctyl succinate, di pentaerythrityl hexacaprylate/hexacaprate, DNA, erythritol, ethoxydiglycol, ethyl linoleate, eucalyptus globulus ) oil, evening primrose ( oenothera ) biennis )) oil, fatty acids, geranium macullatum ( geranium maculatum ) oil, glucosamine, glucose glutamate, glutamic acid, glycereth-26, glycerin, glycerol, glyceryl distearate, glyceryl hydroxystearate, glyceryl laurate (glyceryl laurate), glyceryl linoleate, glyceryl myristate, glyceryl oleate, glyceryl stearate, glycerol stearate SE, glycine, glycol stearate, glycol stearate SE, glycosaminoglyc Glycosaminoglycans, grape ( vitis vinifera ) seed oil, hazel ( corylus americana ) nut oil, hazel ( corylus avellana ) nut oil, hexylene glycol, hyaluronic acid, hybrid safflower ( carthamus tinctorius ) oil, hydrogenated castor oil, hydrogenated coco-glycerides, hydrogenated coconut oil, hydrogenated lanolin, hydrogenated Hydrolyzed Lecithin, Hydrogenated Palm Glyceride, Hydrogenated Palm Kernel Oil, Hydrogenated Soybean Oil, Hydrogenated Tallow Glyceride, Hydrogenated Vegetable Oil, Hydrolyzed Collagen, Hydrolyzed Elastin, Hydrolyzed Glyco Saminoglycan, Hydrolyzed Keratin, Hydrolyzed Soy Protein, Hydroxylate Lanolin, Hydroxyproline, Isocetyl Stearate, Isocetyl Stearoyl Stearate, Isodecyl Oleate, Isopropyl Isostearate, Iso Propyllanolate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isostearamide DEA, isosteric acid, isostearyl lactate, isostearyl neopentanoate, jasmine ( jasminum officinale day ( jasminum officinale )) oil, jojoba ( buxus chinensis ) oil, kelp, kukui ( aleurites molucana ) nut] oil, lactamide MEA (lactamide MEA), laneth-16, laneth-10 acetate, lanolin, lanolic acid, lanolin alcohol, lanolin oil, lanolin wax, lavender ( lavandula angustifolia) angustifolia )) Oil, Lecithin, Lemon ( Citrus Medica Limonum) medica limonum ) oil, linoleic acid, linolenic acid, macadamia ternifolia nut oil, maltitol, chamomile (matricaria) ( chamomilla recutita ) oil, methyl glucose methyl glucose sesquistearate, methylsilanol PCA, mineral oil, mink oil, mortierella oil, myristyl lactate, myristyl myristate, myristyl propio nate, neopentyl glycol dicaprylate/dicaprate, octyldodecanol, octyldodecanol, octyldodecyl myristate, octyldodecyl stearoyl stearate, octyl hydroxystealake, octyl palmitate, octyl salicylate, Octyl stearate, oleic acid, olive ( olea europaea ) oil, orange ( citrus auratiumdulis ) aurantium dulcis ) oil, palm ( elaeis ) guineensis ) oil, palmitic acid, pantethine, panthenol, panthenyl ethyl ether, paraffin, PCA, peach (Prunus persica) persica )) kernel oil, peanut ( arachis hypogaea ) oil, PEG-8 C12-18 ester, PEG-15 cocamine, PEG-150 distearate, PEG-60 glycerin Lyl Isostearate, PEG-5 Glyceryl Stearate, PEG-30 Glyceryl Stearate, PEG-7 Hydrogenated Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-20 Methyl Glucose Sesquistearate, PEG40 Sorbitan Ferroleate, PEG-5 Soy Sterol, PEG-10 Soy Stearol, PEG-2 Stearate, PEG-8 Stearate, PEG-20 Stearate, PEG-32 Stearate, PEG40 Stear lactate, PEG-50 stearate, PEG-100 stearate, PEG-150 stearate, pentadecalactone, peppermint ( mentha piperita ) oil, petrolatum, phospholipids, polyamino sugars Condensate (polyamino sugar condensate), polyglyceryl-3 diisostearate, polyquaternium-24, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate Bate 80, polysorbate 85, potassium myristate, potassium palmitate, propylene glycol, propylene glycol dicaprylate/dicaprate, propylene glycol dioctanoate, propylene glycol dipelargonate, Propylene glycol laurate, propylene glycol stearate, propylene glycol stearate SE, PVP, pyridoxine dipalmitate, retinol, retinyl palmitate, rice (Oryza sativa) oryza sativa )) bran oil, RNA, rosemary ( Rosmarinus officinalis ) officinalis ) oil, rose oil, safflower (carthamus tintorus) tinctorius ) oil, sage (Salvia officinalis) officinalis ) oil, sandalwood ( santalum album ) oil, serine, serum protein, sesame ( sesamum indicum ) oil, shea butter (( butyrospermum ) parkii )), silk powder, sodium chondroitin sulfate, sodium hyaluronate, sodium lactate, sodium palmitate, sodium PCA, sodium polyglutamate, water-soluble collagen, sorbitan laurate, sorbitan oleate, sorbitan Palmitate, sorbitan sesquioleate, sorbitan stearate, sorbitol, soybean ( glycine soja )) oil, sphingolipids, squalane, squalene, stearamide MEA-stearate, stearic acid, stearoxy dimethicone, stearoxytrimethylsilane, stearyl alcohol , stearyl glycyretinate, stearyl heptanoate, stearyl stearate, sunflower ( helianthus annuus ) seed oil, sweet almond ( prunus amygdalus dulcis ) oil, Synthetic Beeswax, Tocopherol, Topoferyl Acetate, Tocopheryl Linoleate, Tribehenin, Tridecyl Neopentanoate, Tridecyl Stearate, Triethanolamine, Tristearin, Urea, Vegetable Oil, Water, Wax, wheat ( triticum bulgar) vulgar e)) germ oil, and ylang ylang ( cananga odorata) odorata )) contains oil.

c. antioxidant

Non-limiting examples of antioxidants that may be used in combination with the compositions of the present invention include acetyl cysteine, ascorbic acid polypeptide, ascorbyl dipalmitate, ascorbyl methylsilanol pectinate, ascorbyl palmitate. Tate, ascorbyl stearate, BHA, BHT, t-butyl hydroquinone, cysteine, cysteine HCI, diamylhydroquinone, di-t-butylhydroquinone, dicetyl thiodipropionate, dioleyl tocopheryl methylsilane Dioleyl tocopheryl methylsilanol, disodium ascorbyl sulfate, distearyl thiodipropionate, ditridecyl thiodipropionate, dodecyl gallate, erythorbic acid, erythorbic acid ester, ethyl ferul Ethyl ferulate, ferulic acid, gallic acid ester, hydroquinone, isooctyl thioglycolic acid, kojic acid, magnesium ascorbate, magnesium ascorbyl phosphate, methylsilanol ascorbate, green tea or natural plant antioxidants such as grape seed extract, nordihydroguaiaretic acid, ox gallate, phenylthioglycolic acid, potassium ascorbyl toropheryl phosphate, potassium sulfate, propyl gallate, quinone, rosemary Acid, sodium ascorbate, sodium bisulfite, sodium erythrobate, sodium metabisulfite, sodium sulfite, superoxide dismutase, sodium thioglycolic acid, sorbityl furfural ), thiodiglycol, thiodiglycolamide, thiodiglycolic acid, thioglycolic acid, thiolactic acid, thiosalicylic acid, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18 , tocopheres-50, tocopherol, tocophersolan (tocophersolan), tocopheryl acetate, tocopheryl linoleate, tocopheryl nicotine yt, tocopheryl succinate, and tris(nonylphenyl)phosphite.

d. structuring agent

In another non-limiting aspect, the compositions of the present invention may include a structuring agent. In certain aspects, the structuring agent helps to provide the rheological properties of the composition that contribute to the stability of the composition. In another aspect, the structuring agent may also function as an emulsifier or surfactant. Non-limiting examples of structuring agents include stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, steric acid, palmitic acid, on average from about 1 to about 21 ethylene oxide units. polyethylene glycol ethers of stearyl alcohol with

e. emulsifier

In certain aspects of the present invention, the compositions of the present invention do not comprise an emulsifier. However, in other aspects, the composition may include one or more emulsifiers. Emulsifiers can reduce the interfacial tension between the phases and can improve the formulation and stability of the emulsion. Emulsifiers can be nonionic, cationic, anionic, and zwitterionic emulsifiers (see McCutcheon's (1986); US Pat. Nos. 5,011,681; 4,421,769; 3,755,560). Non-limiting examples include esters of glycerin, propylene glycol esters, polyethylene glycol fatty acid esters, polypropylene glycol fatty acid esters, sorbitol esters, sorbitan anhydride esters, carboxylic acid copolymers, glucose ethers and esters, ethoxylated ethers. ethers), ethoxylated alcohols, alkyl phosphates, polyethylene fatty acid ether phosphates, fatty acid amides, acyl lactylates, soaps, TEA stearate, DEA olis-3 phosphate, polyethylene glycol 20 sorbitan monolaurate (poly Sorbate 20), Polyethylene Glycol 5 Soya Sterol, Steareth-2, Steareth-20, Steareth-21, Ceteareth-20, PPG-2 Methyl Glucose Ether Distearate, Ceteth-10, Polysorbate 80 , cetyl phosphate, potassium cetyl phosphate, diethanolamine cetyl phosphate, polysorbate 60, glyceryl stearate, PEG-100 stearate, and mixtures thereof.

f. silicone-containing compounds

In a non-limiting aspect, silicon-containing compounds include any member of the family of polymer products having a molecular backbone in which silicon and oxygen atoms are alternately polymerized with side groups attached to silicon atoms. By varying -Si-O- chain length, side groups, and crosslinking, silicones can be synthesized into a wide range of materials. They can vary in concentration from liquid to gel to solid.

Silicone containing compounds that may be used in the context of the present invention include those described herein or known to those skilled in the art. Non-limiting examples include silicone oils (eg, volatile and non-volatile oils), gels, and solids. In another aspect, the silicone containing compound comprises a silicone oil such as a polyorganosiloxane. Non-limiting examples of polyorganosiloxane include dimethicone, cyclomethicone, polysilicon-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, or their The mixture and other organosiloxane materials are included in any proportions given to achieve the desired concentration and application properties according to the intended application (eg, to a particular area such as skin, hair, or eyes). "Volatile silicone oil" includes silicone oil having a low heat of evaporation. For example, generally less than about 50 cal per gram of silicone oil. Non-limiting examples of volatile silicone oils include the following ingredients: Dow Corning 344 Fluid, Dow Corning 345 Fluid, Dow Corning 244 Fluid, and Dow Corning 245 Fluid, Volatile Silicon 7207 (Union Carbide Corp, Danbury, Conn.) cyclomethicone such as; Low viscosity dimethicone, eg, dimethicone having a viscosity of about 50 cst or less (eg, dimethicone such as Dow Corning 200-0.5 cst Fluid). This Dow Corning Fluid is commercially available from Dow Corning Corporation, Midland, Michigan. Cyclomethicone and dimethicone are mixtures of fully methylated linear siloxane polymers end-blocked with trimethylsiloxy units and cyclin dimethyl polysiloxane compounds, respectively, in the Third Edition of the CTFA Cosmetic Ingredient Dictionary (see incorporated into). Other non-limiting volatile silicone oils that may be used in the context of the present invention include General Electric Co., Silicone Products Div., Waterford, N.Y. and SWS Silicones Div. of Stauffer Chemical Co., Adrian, Michigan.

g. essential oil

Essential oils include oils derived from herbs, flowers, trees, and other plants. These oils generally appear as tiny droplets between the cells of the plant, and can be obtained by a variety of methods known to those skilled in the art (eg, steam distillation, chilling (eg, extraction with fat), happy, solvent extraction). , or mechanical compression). When these types of oils are exposed to air they tend to evaporate (eg, volatile oils). As a result, many essential oils are colorless, but can oxidize and darken over time. Essential oils are insoluble in water and soluble in alcohols, ethers, fixed oils (vegetables), and other organic solvents. Typical physical properties found in essential oils include boiling points varying from about 160 to 240° C. and densities ranging from about 0.759 to 1.096.

Essential oils are generally named from the plant in which the oil is found. For example, rose oil or peppermint oil is derived from a rose or peppermint plant, respectively. Non-limiting examples of essential oils that may be used in the context of the present invention include sesame oil, macadamia nut oil, tea tree oil, evening primrose oil, Spanish sage oil, Spanish rosemary oil, coriander oil, thyme oil oil), pimento berries oil, rose oil, anise oil, balsam oil, bergamot oil, rosewood oil, cedar oil, chamomile oil, sage oil, clary sage oil, clove oil, cypress oil, eucalyptus oil, fennel oil, sea fennel oil, frankincense oil, geranium oil, ginger oil, grapefruit oil, Jasmine oil, juniper oil, lavender oil, lemon oil, lemongrass oil, lime oil, mandarin oil, marjoram oil, myrrh oil, neroli oil, orange oil, patchouli oil (patchouli oil), pepper oil, black pepper oil, petitgrain oil, pine oil, rose otto oil, rosemary oil, sandalwood oil, spearmint oil, persimmon oil, vetiver oil, wintergreen oil (wintergreen oil), or ylang ylang. Other essential oils known to those skilled in the art are also contemplated as useful in the context of the present invention.

h. thickener

Thickening agents, including thickeners or gelling agents, include substances capable of increasing the viscosity of the composition. Thickeners include those capable of increasing the viscosity of the composition without substantially modifying the efficacy of the active ingredients in the composition. Thickeners may also increase the stability of the compositions of the present invention. In certain aspects of the invention, the thickening agent comprises hydrogenated polyisobutene or trihydroxystearin, or a mixture of the two.

Non-limiting examples of additional thickeners that may be used in the context of the present invention include carboxylic acid polymers, crosslinked polyacrylate polymers, polyacrylamide polymers, polysaccharides, and gums. (gums) are included. Examples of carboxylic acid polymers include crosslinked compounds comprising acrylic acid, substituted acrylic acid, and one or more monomers derived from esters and salts of these acrylic acids and substituted acrylic acids, wherein the crosslinking agent ) contains two or more carbon-carbon double bonds and is derived from polyhydric alcohols (see US Pat. Nos. 5,087,445; 4,509,949; 2,798,053; CTFA International Cosmetic Ingredient Dictionary, Fourth edition, 1991, pages 12 and 80). Examples of commercially available carboxylic acid polymers include carbomers, homopolymers of acrylic acid crosslinked with sucrose or pentaerythritol allyl ether (e.g., B. F. Goodrich's Carbopol™ 900 series). ).

Non-limiting examples of cross-linked polyacrylate polymers include cationic and nonionic polymers. Examples are described in US Pat. Nos. 5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379.

Non-limiting examples of polyacrylamide polymers (including nonionic polyacrylamide polymers including substituted branched or unbranched polymers) include polyacrylamide, isoparaffin and laureth-7, acrylic acid and substituted acrylic acid with acrylamide and substituted a multi-block copolymer of acrylamide.

Non-limiting examples of polysaccharides include cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxy ethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof. Another embodiment is that the hydroxy group of the cellulosic polymer is hydroxyalkylated (preferably hydroxyethylated or hydroxypropylated) alkyl-substituted cellulose. Generally these polymers are ethers of hydroxyalkylcelluloses and C10-C30 straight or branched chain alcohols. Other useful polysaccharides include scleroglucans comprising a linear chain of (1-6) every 3 units of linked glucose and (1-3) linked glucose units.

Non-limiting examples of gums that can be used with the present invention include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan. , dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluronic acid, hydrated silica, hydropropyl Chitosan, hydropropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.

i. preservative

Non-limiting examples of preservatives that may be used in the context of the present invention include polyquaternium-1 and benzalkonium halides (eg, benzalkonium chloride "BAC" and benzalkonium bromide) and quaternary ammonium preservatives, such as parabens (eg, methylparaben and propylparaben), phenoxyethanol, benzyl alcohol, chlorobutanol, phenol, sorbic acid, thimerosal, or combinations thereof. .

2. Pharmaceutical Ingredients

Pharmaceutically active agents are also contemplated for use with the compositions of the present invention. Non-limiting examples of pharmaceutical actives include antiacne agents, agents used to treat rosacea, analgesics, anesthetics, anorectals, antihistamines, non-steroids Anti-inflammatory agents, including sexual anti-inflammatory drugs, antibiotics, antifungals, antiviral agents, antibacterial agents, anti-cancer actives, scabicides, pediculicides, anticancer drugs, sweating Antiperspirants, antipruritics, antipsoriatic agents, antiseborrheic agents, bioactive proteins and peptides, burn treatment agents, cauterizing agents, depigmenting agents, depilatory agents (depilatories), diaper rash treatment agent, enzyme, hair growth promoter, hair growth retardant including DFMO and salts and analogs thereof, hemostatic agent, keratolytic agent, stomatitis treatment agent, lip rash treatment agent, tooth and periodontal treatment agent, photosensitizer, skin protectant /blockers, steroids including hormones and corticosteroids), sunburn treatment, sunscreen, transdermal actives, nasal actives, vaginal actives, wart treatment, wound treatment ( wound treatment agents), wound healing agents, and the like.

F. kit

It is also contemplated that kits may be used in certain aspects of the invention. For example, the compositions of the present invention may be included in a kit. The kit may include a container. Containers include bottles, metal tubes, laminate tubes, plastic tubes, dispensers, pressurized containers, barrier containers, packages, compartments, lipstick containers, and compact containers. , cosmetic pans capable of holding the cosmetic composition, or other types of containers, such as injection or blow molded plastic containers, within which the dispersion or composition or desired bottle, dispenser, or package is held. can The kit and/or container may include indicia on the surface. For example, the indicia may be a letter, a phrase, an abbreviation, a photograph, or a symbol.

The container may provide a predetermined amount of the composition. In other embodiments, the container may be squeezed (eg, metal, laminate or plastic tube) to provide the desired amount of composition. The composition may be provided as a spray, aerosol, liquid, fluid, or semi-solid. The container may have spray, pump, or squeeze mechanisms. The kit may also include instructions for using the kit's components as well as instructions for use of any other composition contained in the container. Instructions may include explanations of how to maintain, use, and apply the composition.

Example

The following examples are included to illustrate certain non-limiting aspects of the invention. It should be appreciated by those skilled in the art that the following representative techniques discovered by the inventors to function well in the practice of the present invention are disclosed in the Examples. However, those skilled in the art should recognize that changes may be made in the specific embodiments disclosed herein and still obtain the same or similar results without departing from the spirit and scope of the present invention.

Example One

of the compositions non-limiting Examples ( Non - limiting Examples of Compositions )

Echinacea Purpuria purpurea ) extract (Naturex (France)) was found to bind human cannabinoid receptor type 2 (CBr2) in vitro . It was also shown to be an enzyme inhibitor using an antioxidant and lipoxygenase (LO) assay using the Trolox equivalent antioxidant capacity (TEAC) test. These data suggest that this extract may inhibit sensory nerve fibers that control itching in the skin (data not shown). Silybum marianum extract (Provital SA (SPAIN)) was found to inhibit fatty acid amide hydrolase (FAAH) activity. FAAH is known to destroy cannabinoids, which in turn can activate CBr2. Silybum marianum extract also inhibits COX-1 and COX-2 (LO assay), and keratinocyte inflammatory cytokines including TNFalpha, CGRP, IL-1, IL-6, and IL-8 It inhibits keratinocyte inflammatory cytokines and has been found to be an antioxidant (ORAC test, TEAC test). The inventors have found that the combination of these extracts works in a synergistic manner to increase and maintain CBr2 activity, which can reduce the sensation of itchy or itchy skin.

Glycerin is a known moisturizer. Cetylhydroxyproline palmitamide/steric acid/ Brassica campestris sold under the trade name SymRepair by Symrise Mixtures comprising (rapeseed) sterols are also known to have skin moisturizing properties.

The inventors believed that by combining each of the above ingredients into a single composition, the overall effect would be treating dry, cracked, or scaly skin while also treating itchy skin. One skilled in the art can also use the testing vehicle of Tables 1 and 2 to ascertain the effects of a combination of these ingredients on itchy skin, or dry, scaly, or cracked skin.

ingredient % Concentration (weight) Phase A water Appropriate amount (q.s. to) 100 Xanthum gum 0.1 M-parabens 0.15 P-parabens 0.1 citric acid 0.01 Phase B cetyl alcohol 4.0 Glyceryl Stearate + PEG 100 4.0 Octyl Palmitate 4.0 dimethicone 1.0 Tocopheryl Acetyl 0.2 Phase C Active ingredients** 5.0

*Spray xantum gum in water and mix for 10 minutes. After that, add all ingredients of Phase A and heat to 70-75°C. Separately add all items of Phase B to a beaker and heat to 70-75°C. Mix Phase A and Phase B at 70-75°C. Continue mixing and allow composition to cool to 30°C. Then add Phase C ingredients while mixing.**Any active ingredients described herein (or combinations thereof) may be used. For example, the active ingredients include Echinacea purpurea extract, Silybum marianum ) extract, glycerin, and a mixture comprising cetylhydroxyproline palmitamide/steric acid/ Brassica campestris (rapeseed) sterols. In other breeds, the combination is Echinacea purpurea extract, Silybum marianum ) extract, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (rapeseed) sterols. Although the total amount of active ingredients in the Table 1 formulation is 5% by weight, the amount of active ingredients may be increased or decreased to achieve the desired result, wherein the amount of water may be increased/decreased accordingly (e.g. For example, the appropriate amount) is considered.

Ingredient % Concentration (weight) Phase A water q.s. to 100 M-parabens 0.2 P-parabens 0.1 Na2EDTA 0.1 shea butter 4.5 Vaseline 4.5 glycerin 4.0 propylene glycol 2.0 Finsolve TN 2.0 Phase B Sepigel 305 2.0 Phase C active ingredient(s)** 2.0

*Add the components of Phase A to a beaker and heat to 70-75°C while mixing. After that, phase B component was added to Phase A, and cooled to 30 °C with mixing. Then add Phase C ingredients while mixing.**Any active ingredients described herein (or combinations thereof) may be used. For example, the active ingredients include Echinacea purpurea extract, Silybum marianum ) extract, rosemary acid-α-D-glucoside, glycerin, and cetylhydroxyproline palmitamide/steric acid/Brassica campestris ( Brassica ) campestris ) (rapeseed) sterols. In another aspect, the combination comprises Echinacea purpurea extract, Silybum marianum ) extract, and a mixture comprising cetylhydroxyproline palmitamide/steric acid/ Brassica campestris (rapeseed) sterols. Although the total amount of active ingredients in the Table 2 formulation is 2% by weight, the amount of active ingredients may be increased or decreased to achieve the desired result, wherein the amount of water may be increased/decreased accordingly (e.g. For example, the appropriate amount) is considered.

Example 2

in vivo ( In Vivo ) data

In vivo ( In The in vivo test is Echinacea purpurea ) extract 0.50% by weight, Silybum marianum ) extract 1.0% by weight, cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (Rapeseed) was carried out using a composition containing 2.0% by weight of a mixture containing sterols, and 15.0% by weight of glycerin. The Echinacea Purpuria ( Echinacea purpurea ) extract from Naturex (France) under the trade name ECHINACEA PURPUREA HERB PE, Silybum marianum extract under the trade name PRONALEN SILYMARIN from Provital SA (SPAIN), and cetylhydroxyproline palmitamide/steric acid/ Brassica campestris A mixture comprising (rapeseed) sterols was purchased from Symrise (Germany) under the trade name SymRepair. In particular, a two-week clinical evaluation of dryness, texture, and itching was performed on Echinacea ( Echinacea ). purpurea extract, Silybum marianum extract, glycerin, and cetylhydroxyproline palmitamide / steric acid / Brassica campestris ( Brassica ) campestris ) (rapeseed) sterols were incorporated, and preservative-free proprietary base lotion formulation ("Vinny Base") was used. Untreated legs were used as controls.

Study Design and Methods: A study was conducted and completed among 22 female panelists between 18 and 69 years of age and Caucasian. The panelists read and signed the informed consent form. The study required four visits to the testing facility over a two-week period. Visits were as follows: Day 0 (baseline), Day 2, Day 7, and Day 14. Prior to each measurement, panelists were equilibrated in the test environment for 15 minutes. This study required a one-week washout period prior to the baseline visit, and panelists were instructed to wash the lower leg with an Ivory ^TM soap bar at least twice a day, and use warm water to rinse. Panelists were instructed to apply the product to the lower side of one leg according to a treatment randomization code. The untreated leg served as a control. The results of this study are provided in Tables 1-4.

visual grading _ _ Grading ): During all visits, panelists assessed Visual Analogue Scale (VAS) (Mild = 1-3.9, moderate = Visually using 4-6.9 and severe = 7-10) and an ordinal scale (0 = no evidence of dryness to 4 = severe flaking, flaking and/or fissures). was evaluated as

Subjective Itch Questionnaire: All panelists were asked to complete a subjective itch questionnaire to assess the intensity of skin itch they perceived based on VAS scales 0 (none) to 10 (strong) at baseline and at the 14th (final) visit only.

Vapometer measurement : grading is Transdermal skin water loss (TEWL) measurements using a vapometer were performed and followed.

Product Application: Panelists were instructed to apply the product to the lower lateral area of one leg twice daily for two weeks. Panelists were asked to refrain from prolonged sun exposure and the use of any moisturizers, shaving creams and anti-itch products on their legs from 1 week before baseline until the end of the study. They were also asked to refrain from shaving the lower legs prior to 48 hours from all visits. Approximately one hour prior to each visit, the lower legs were requested to be washed using an Ivory ^™ soap bar.

Statistical Analysis: Visual grading score changes and vapometer data obtained on days 2, 7, and 14 were compared to baseline using a paired t-test. Statistical significance was considered at p values ≤ 0.05.

: Experts on treatment and control grading and subjective itch questionnaire skin characteristics
( Skin Attributes ) Average percentage improvement compared to baseline over two weeks
[Percentage of panelists showing improvement] Day 2
Day 7
Day 14
process unprocessed process unprocessed process unprocessed dry 19% *
[32%] ni ^{^}
[NI] 50% *
[82%] ni ^{^}
[NI] 69% *
[91%] ni ^{^}
[NI] texture 24% *
[86%] NS
[NS] 47% *
[100%] 11% *
[73%] 54% *
[100%] NS
[NS] Itch - subjective questionnaire NA NA NA NA 64% *
[95%] NS
[NS]

* Statistical significance at 95% confidence level compared to the standard, ^ significantly worse compared to the standard, NI : No improvement, NS : No significance at 95% confidence level, NA : None

: Mean visual between treatment and control grading and subjective itchy questionnaire scores
skin condition treatment for 2 weeks and unprocessed mean score between groups dry texture Itch - subjective questionnaire process unprocessed p value process unprocessed p value process unprocessed p value standard 2.09 2.09 1.00 6.66 6.76 0.66 4.69 5.02 0.14
2 days 1.66 2.23 0.001 ^￥ 5.03 6.37 0.001 ^￥
NA NA
NA
7 days 1.04 2.38 <0.001 ^￥ 3.50 5.99 <0.001 ^￥ NA NA
NA
14 days 0.61 2.61 <0.001 ^￥ 2.96 6.49 <0.001 ^￥ 1.54 4.59 <0.001 ^￥

^￥ 95% statistical significance at the confidence level, NA : None

: for treatment and control compared to baseline TEWL analysis Average percentage improvement compared to baseline over two weeks
[Percentage of panelists showing improvement] TEWL measurement process unprocessed standard NS
[NS] NS
[NS] 2 days NS
[NS] NS
[NS] 7 days NS
[NS] NS
[NS] 14 days NS
[NS] ni ^{^}
[NI]

^ Significantly worse at 95% confidence interval compared to baseline, NS : No significance at 95% confidence level, NI : no improvement

: Mean TEWL for treatment and control reading mean between 2 groups over 2 weeks TEWL reading TEWL measurement process unprocessed p value standard 5.95 5.99 0.95 2 days 5.35 5.65 0.67 7 days 5.74 6.64 0.11 14 days 6.17 8.31 0.03 ^†

^† Statistically significant cream at 95% confidence level significantly improved skin dryness and skin texture at days 2, 7 and 14 compared to baseline and untreated groups. The untreated group did not show any improvement in skin dryness and texture after 2 weeks compared to baseline. Based on the self-assessed itch questionnaire, itch intensity showed a statistically significant improvement at the 14-day visit compared to baseline in the treatment group. However, there was no significant change in itch intensity in the untreated group after 2 weeks. The anti-itch cream did not significantly improve the skin film in the treatment group for 2 weeks compared to baseline. However, the anti-itch cream was significantly better at maintaining the skin film at 7 and 14 days compared to the untreated group. The skin film deteriorated significantly in the untreated group compared to baseline at 2 weeks.

Example 3

analyzes

In addition to the assays mentioned above, the efficacy of a combination of ingredients disclosed throughout the specification and claims can be determined using the following assays.

Erythema Assay: An assay to measure reduction in skin flushing can be assessed using a Minolta Chromometer. Skin erythema may be induced by applying a 0.2% solution of sodium dodecyl sulfate to the subject's forearm. The area was protected by an occlusive patch for 24 hours. After 24 hours, the patch was removed and irritation-induced flushing was measured with a* of the Minolta Chroma Meter. It can be calculated using the value. above a* The value measures the change in skin color in the redness area. Immediately after reading, the area was treated with the composition of the present invention. Repeat measurements are performed at regular intervals to determine the ability of the formula to reduce flushing and irritation.

Skin moisture / hydration analysis: Skin hydration/hydration benefits can be measured using impedance measurements with a Nova Dermal Phase Meter. The impedance meter measures changes in skin moisture content. The outer layer of skin has distinct electrical properties. When the skin is dry, it conducts electricity very low. As the skin becomes more hydrated, an increase in conductivity occurs. Thus, changes in skin impedance (related to conductivity) can be used to estimate changes in skin hydration. Units can be adjusted for each test day's equipment instructions. It can also be an indication of temperature and associated humidity. Subjects can be assessed as follows: can be equilibrated in a room with defined humidity (eg 30-50%) and temperature (eg 68-72° C.) prior to measurement. Three separate impedance readings can be performed, recorded, and averaged for each part of the face. The T5 setting can be used on the impedance meter to average the impedance values of every five seconds application to the face. Changes can be reported as statistical changes and significance.

Analysis of Skin Transparency and Reduction of Spots and Age Spots: Skin clarity and reduction of spots and age spots can be assessed using a Minolta Chromometer. Skin color change can be calculated using the a* value of the Minolta Chroma Meter to determine the potential for irritation due to product treatment. The a* value measures the skin color change in the redness area. This is used to determine whether the composition reduces irritation or not. The measurement can be made on each side of the skin and averaged as left and right facial values. In addition Skin transparency can be measured using a Minolta Meter. The measurement is a combination of the a*, b and L values of the Minolta Meter, which is related to skin brightness and closely correlates with skin softness and moisture. Skin reading is performed as above. In one non-limiting aspect, skin transparency may be described as L/C, where C is the chroma and is defined as ( ^{a 2 +} b ² ) ^1/2 .

Analysis of Dry Skin, Surface Fine Lines, Skin Smoothness, and Skin Tone: Dry skin, surface fine lines, skin smoothness, and skin tone can be assessed with clinical grading techniques. For example, the clinical grading of dry skin can be determined by a five-point standard Kligman Scale: (0) skin is soft and moist; (1) the skin is generally visible without visible dryness; (2) the skin has no visible dead skin cells and feels slightly dry to the touch; (3) the skin feels dry, rough, has some scaling and a slightly whitish appearance; and (4) the skin feels very dry, rough, and has a scaly and slightly whitish appearance. Assessments can be made independently by the two clinicians and can be averaged.

Clinical Grading Analysis of Skin Tone: Clinical grading of skin tone can be performed via a 10-point analog numerical scale: (10) even skin of uniform, pinkish brown). No dark, erythematous, or scaly patches when examined with a hand held magnifying lens. When touched, the microtexture of the skin is very uniform; (7) Even skin tone observed without magnification. No scaly areas, but discoloration due to slight pigmentation or erythema. no discoloration greater than 1 cm in diameter; (4) Easily detectable both skin discoloration and uneven texture. Slightly scaly. rough skin feel in some areas; and (1) uneven skin color and feel. Many areas of scaliness, discoloration, and also hypopigmented, erythematous or dark spots. Uneven color over 1 cm in diameter over a large area. Assessments can be made independently by the two clinicians and can be averaged.

Analysis of clinical grading of skin smoothness: The clinical grading of skin smoothness can be analyzed via a 10-point analog numerical scale: (10) softness, skin is moist and shiny, upon dragging a finger across the surface no resistance; (7) some softness, some resistance; (4) roughness, visibly altered, rubbing upon rubbing; and (1) rough, keratinous, uneven surfaces. Assessments can be made independently by the two clinicians and can be averaged.

Packman et al. ( 1978) and analysis of skin smoothness and wrinkle reduction : Skin smoothness and wrinkle reduction are described in Packman et al. (1978) can be evaluated visually. For example, at each subject visit, the depth, shallowness, and total number of facial wrinkles (SFLs) on the surface of each subject can be carefully counted and recorded. Numerical scores were obtained by multiplying a number factor times a depth/width/length factor. Values were obtained for the corners of the eye and mouth (left and right) and added together as the total number of wrinkles.

Hargens Ballistometer and Skin Elasticity Analysis: Skin elasticity can be measured using a Hargens ballistometer, a device that evaluates the elasticity and elasticity of the skin by dropping a small body onto the skin and recording the first and second rebound peaks. Ballistometry is a small, lightweight probe with a relatively blunt tip (4 square mm-contact surface). The probe penetrates slightly into the skin and results in measurements dependent on the properties of the outer layers of the skin, including the stratum corneum and outer epidermis and some dermal layers.

Gas Bearing Electrodynamometer and skin softness/suppleness analysis: Skin softness/suppleness can be evaluated using a Gas Bearing Electrodynamometer, a device that measures the stress/strain properties of the skin. The viscoelastic properties of skin are correlated with skin moisture. Measurements can be obtained by attaching the probe to the skin surface with double-sided tape on a pre-determined area of the cheek area. A force of approximately 3.5 gm can be applied flatly to the skin surface, and the skin displacement is accurately measured. Skin softness can then be calculated and expressed as DSR (Dynamic Spring Rate in gm/mm).

Replicas and Appearance Lines and Wrinkles Analysis: Appearance lines and wrinkles in the skin can be evaluated using Replicas, which are impressions of the skin's surface. A material such as silicone rubber may be used. Refrica can be analyzed by image analysis. Noticeable changes in lines and wrinkles form a silicone replica from the subject's face and can be objectively quantified through replica image analysis using a computerized image analysis system. Replica may be performed in the eye area and neck area, and may be captured with a digital camera using low-angle incident light. The digital images can be analyzed with an image processing program, and the areas of the replicas covered with wrinkles or fine lines are determined.

Profilometer / Stylus Method and Surface Contour Analysis of Skin: The surface contour of the skin can be measured using a profilometer /Stylus method. This involves illuminating or dragging the stylus across the replica surface. The vertical displacement of the stylus can be input into a computer through a distance transducer, and a skin cross-sectional analysis profile can be generated as a two-dimensional curve after scanning a fixed length of the replica. These scans can be repeated any number of times along a fixed axis to generate a simulated 3-D picture of the skin. 10 random sections of the replica using the stylus technique can be obtained and combined to generate average values. The values of interest include Ra, which is the arithmetic mean of all roughness (height) values calculated by integrating the profile height over the average profile height. Rt is the maximum vertical distance between the highest peak and lowest trough, and Rz is the average peak amplitude minus the average amplitude height. Values are given as adjusted values in mm. The equipment should be standardized by scanning metal standards of known values before each use. The Ra value can be calculated with the following equation: Ra = normalized roughness; l m = traverse (scan) length; and y = absolute value of the position of the profile with respect to the average profile height (x-axis).

MELANODERM ^™ Assay: In one non-limiting aspect, the efficacy of the compositions of the present invention can be assessed using a skin analog, such as, for example, MELANODERM ^™ . Melanocytes, one of the cells of the skin analog, stain positively when exposed to L-dihydroxyphenyl alanine (L-DOPA), a precursor of melanin. The skin analog, MELANODERM ^™ , can be treated with a variety of bases comprising the whitening agents and compositions of the present invention or the base alone as a control. Alternatively, an untreated sample of the skin analog can be used as a control.

ORAC Analysis: The Oxygen Radical Absorption (or Absorbance) Capacity (ORAC) of aromatic skin active ingredients and compositions can also be analyzed by measuring the antioxidant activity of these ingredients or compositions. This assay can quantify the duration and extent of inhibition of the activity of oxidizing agents such as oxygen radicals, which are known to cause damage to cells (eg, skin cells). The ORAC values of aromatic skin active ingredients and compositions can be determined by methods known to those skilled in the art (see US Publication Nos. 2004/0109905 and 2005/0163880; Cao et al . al . (1993)), all incorporated by reference). In summary, Cao et al . al . (1993) of the antioxidant compounds of the test substances inhibiting the decrease in B-phycoerythrm (B-PE) fluorescence induced by the peroxyl radical generator, AAPH. measure your ability

Matrix metalloproteinase enzyme activity ( MMP3 ; MMP9 ) assay: in vitro ( in in vitro ) matrix metalloprotease (MMP) inhibition assay. MMPs are extracellular proteases that play a role in many common and disease states due to their broad substrate specificity. MMP3 substrates include collagen, fibronectins and laminin; Whereas MMP9 substrates include collagen VII, fibronectin, and laminin. Using the Colorimetric Drug Discovery Kit for MMP3 (AK-400) and MMP-9 (AK-410) from BioMol International, this assay was performed using the chromogenic substrate Ac-PLG-[2-mercapto-4-methyl -pentanoyl]-LG-OC2H5)5,6 is designed to measure the proteolytic activity of MMPs using thiopeptides. The MMP cleavage site peptide bond is replaced by a thioester bond of a thiopeptide. Hydrolysis of this bond by MMP produces a sulfhydryl group, which is DTNB [5,5'-dithiobis(2-nitrobenzoic acid), to form 2-nitro-5-thiobenzoic acid, Ellman's reagent], which can be detected by absorbance at 412 nm (ε=13,600 M-1 cm-1 at pH 6.0 and above 7).

B16 Pigmentation Assay: Melanogenesis is the process by which melanocytes produce melanin, a naturally produced pigment that gives color to skin, hair, and eyes. Inhibition of melanogenesis is beneficial for preventing skin darkening and lightening the dark spots associated with aging. This bioassay uses B16-F1 melanocytes (ATCC), an immortalized mouse melanoma cell line, to analyze the effects of compounds on melanogenesis. The endpoint of this assay is a spectrophotometric measurement of cell viability and melanin production. B16-F1 melanocytes (ATCC) can be cultured in standard DMEM growth medium with 10% fetal bovine serum (Mediatech) at 37° C., 10% CO ₂ , then the active ingredient disclosed herein. , a combination of ingredients, or any of the compositions having such combinations for 6 days. Following incubation, melanin secretion is measured as absorbance at 405 nm, and cell viability is quantified.

Collagen Stimulation Assay: Collagen is an extracellular matrix protein critical to skin structure. Increased collagen synthesis helps improve skin firmness and elasticity. This bioassay is assayed for the production of procollagen peptide (a precursor of collagen) by human epidermal fibroblasts, any one of the active ingredients, combinations of ingredients, or compositions having such combinations. can be used to test the effectiveness of The endpoint of this assay is a spectrophotometric measurement that reflects cell viability and the presence of procollagen peptides. This assay uses quantitative sandwich enzyme immunoassay techniques in which monoclonal antibodies specific for procollagen peptides are pre-coated onto microplates. Standards and samples can be pipetted into wells and any procollagen peptides present are bound by immobilized antibodies. After washing away all unbound material, an enzyme-linked polyclonal antibody specific for the procollagen peptide may be added to the wells. After washing to remove all unbound antibody-enzyme reagent, substrate solution can be added to the wells and the color is the amount of bound procollagen peptide in the initial step using a microplate reader for detection at 450 nm. appears in proportion to Color development can be stopped and color intensity can be measured. Subconfluent normal adult epidermal fibroblasts (Cascade Biologics) can be cultured in standard DMEM growth medium with 10% fetal bovine serum (Mediatech) at 37 °C, 10% CO ₂ , and the Then the combination of ingredients disclosed herein, or each of the compositions having the combinations, is treated for 3 days. Following incubation, cell culture medium can be collected and the amount of procollagen peptide secretion is quantified using a sandwich enzyme-linked immunosorbent assay (ELISA) from Takara (#MK101).

Tumor Necrosis Factor Alpha ( TNF -α) Assay: The prototype ligand of the TNF superfamily, TNF-α, is a pleiotropic cytokine that plays an important role in inflammation. Their increased expression is associated with up regulation of pro-inflammatory activity. This bioassay can be used to analyze the effect of any one of the active ingredients, combinations of ingredients, or compositions having such combinations, disclosed herein on the production of TNF-α by keratinocytes of the human epidermis. The endpoint of this assay may be a spectrophotometric measurement that reflects cell viability and the presence of TNF-α. This assay utilizes quantitative sandwich enzyme immunoassay techniques in which monoclonal antibodies specific for TNF-α are pre-coated on microplates. Standards and samples can be pipetted into the wells and any TNF-α present is bound by the immobilized antibody. After washing away all unbound material, an enzyme-linked polyclonal antibody specific for TNF-α may be added to the wells. After washing to remove all unbound antibody-enzyme reagent, substrate solution can be added to the wells and the color is the amount of bound TNF-α in the initial step using a microplate reader for detection at 450 nm. appears in proportion to Color development can be stopped and color intensity can be measured. Keratinocytes of sub-synthetic normal adult epidermis (Cascade Biologics) were cultured in EpiLife standard growth medium (Cascade Biologics) at 37° C., 10% CO ₂ , and phorbol 12-myristate 13- acetate) (PMA, 10 ng/ml, Sigma Chemical, #P1585-1MG) and the active ingredients disclosed herein, combinations of ingredients, or any of the compositions having such combinations for 6 hours. PMA was shown to cause a dramatic increase in TNF-α secretion, which peaked at 6 hours post treatment. Following incubation, cell culture medium can be collected and the amount of TNF-α secretion is quantified using a sandwich enzyme-linked immunosorbent assay (ELISA) from R&D Systems (#DTA00C).

Antioxidant ( AO ) Assay: An in vitro bioassay measuring the total antioxidant capacity of any one of the ingredients, combinations of ingredients, or compositions having such combinations disclosed herein. This assay relies on the ability of the antioxidant of the sample to inhibit the oxidation of ABTS ^® (2,2'-azino-di-[3-ethylbenzothiazoline]) to ABTS ^® + by metmyoglobin. The antioxidant system of living organisms includes enzymes such as superoxide dismutase, catalase, and glutathione peroxidase; macromolecules such as albumin, ceruloplasmin, and ferritin; and many small molecules including ascorbic acid, α-tocopherol, β-carotene, reduced glutathione, uric acid, and bilirubin. The sum of endogenous and food-derived antioxidants represents the total antioxidant capacity of the extracellular fluid. The collaboration of all other antioxidants provides better protection against attack by active oxygen or nitrogen radicals than any single compound alone. Therefore, the overall antioxidant capacity may provide more valid biological information compared to that obtained by measurement of individual components, taking into account the cumulative effect of all antioxidants in plasma and body fluids. can The antioxidant capacity of the samples to prevent ABTS ^® oxidation was compared to Trolox, a water-soluble tocopherol analogue, and quantified in molar Trolox equivalents. Antioxidant Capacity Kit #709001 from Cayman Chemical (Ann Arbor, Michigan USA) is a biometric for measuring the total antioxidant capacity of each of the active ingredients, combinations of ingredients, or any one of the compositions having such combinations, disclosed herein. others ( in in vitro ) can be used as bioassays. This protocol can be followed according to the manufacturer's recommendations. This assay relies on the ability of the antioxidant of the sample to inhibit the oxidation of ABTS ^® (2,2'-azino-di-[3-ethylbenzothiazoline]) to ABTS ^® + by metmyoglobin. The antioxidant ability of the sample to prevent ABTS ^® oxidation can be compared to Trolox, a water-soluble tocopherol analogue, and quantified in molar Trolox equivalents.

Mushroom tyrosinase activity assay: In mammalian cells, tyrosinase catalyzes two steps in the multistep biosynthesis of melanin pigment from tyrosine (and from dopachrome polymerization). Tyrosinase is located in melanocytes and produces melanin (aromatic quinone compounds) that gives color to skin, hair, and eyes. Purified mushroom tyrosinase (Signa) is its (its) substrate L-Dopa ( Fisher). Pigment information can be assessed by colorimetric plate reading at 490 nm. The percentage of inhibition of mushroom tyrosinase activity can be calculated compared to an untreated control to determine the ability of the test components or combinations thereof to inhibit the activity of the purified enzyme. Test extract inhibition was compared with kojic acid (Sigma).

Cyclooxygenase ( COX ) Assay: In vitro cyclooxygenase-1 and -2 (COX-1, -2) inhibition assay. COX is a bifunctional enzyme that exhibits both cyclooxygenase and peroxidase activity. Cyclooxygenase activity converts arachidonic acid to hydroperoxy endoperoxide (prostaglandin G2; PGG2), and the peroxidase component responds to endoperoxide (prostaglandin H2; PGH2) alcohols, precursors of prostaglandins, thromboxanes, and prostacyclins. This COX Inhibitor screening assay measures the peroxidase component of cyclooxygenase. Peroxidase activity is assayed colorimetrically by monitoring the expression of oxidized N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD). This inhibitor screening assay involves both COX-1 and COX-2 enzymes to screen for isozyme-specific inhibitors. A Colormetric COX (ovine) Inhibitor screening assay (#760111, Cayman Chemical) was used in the activity of a purified cyclooxygenase enzyme (COX-1 or COX-2) as disclosed herein. Each of the active ingredients with combinations can be used to analyze the effect of any one of the combinations of ingredients or compositions. Purified enzyme, heme and test extracts can be mixed in assay buffer and incubated with shaking at room temperature for 15 minutes, according to the manufacturer's instructions. Following incubation, arachidonic acid and a colorimetric substrate may be added to initiate the reaction. Color progression can be assessed by colorimetric plates at 590 nm. The percent inhibition of COX-1 or COX-2 activity can be calculated compared to untreated controls to determine the ability of the test extracts to inhibit the activity of the purified enzyme.

Lipoxygenase ( LO ) Assay: In vitro lipoxygenase (LO) inhibition assay. LOs are non-heme iron-containing dioxygenases that catalyze the addition of molecular oxygen to fatty acids. Linoleate and arachidonate are important substrates of LO in plants and animals. Arachidonic acid can then be converted to a hydroxyeicosotrienenoic acid (HETE) derivative, which is then converted to leukotirenes, a potent inflammatory mediator. This assay provides an accurate and convenient method for screening lipoxygenase inhibitors by measuring hydroperoxides produced from incubation of arachidonic acid with lipoxygenase (5-, 12-, or 15-LO). The colorimetric LO inhibitor screening kit (#760700, Cayman Chemical) can be used to determine the ability of each, combination of ingredients, or any one of the compositions having such combinations of active ingredients disclosed herein to inhibit enzymatic activity. Purified 15-lipoxygenase and test components can be mixed in assay buffer and incubated with shaking for 10 minutes at room temperature. Following incubation, arachidonic acid can be added to initiate the reaction and the mixture is incubated for an additional 10 minutes at room temperature. A colorimetric substrate can be added to terminate the catalytic reaction, and color progression is assessed by fluorescence plate reading at 490 nm. The percentage inhibition of lipoxygenase activity is compared to an untreated control to determine the ability of each, combination of ingredients, or any one of the compositions having such combinations of active ingredients disclosed herein to inhibit the activity of the purified enzyme. can be calculated by

Elastase Assay : The EnzChek® Elastase Assay (Kit# E-12056 ) from Molecular Probes (Eugene, Oregon USA) is used for each of the active ingredients disclosed herein, a combination of ingredients, or compositions having such combinations. It can be used as an in vitro enzyme inhibition assay to measure inhibition of any one elastase activity. The EnzChek kit contains soluble bovine neck ligament elastin that can be labeled with a dye that can quench the fluorescence of the conjugate. The non-fluorescent substrate can be digested by elastase or other proteolytic enzymes to obtain highly fluorescent fragments. The result of increasing fluorescence can be monitored with a fluorescence microplate reader. The degradation products in the elastin matrix have an absorbance maximal at ˜550 nm and fluorescence emission maxima at ˜515 nm. When using the EnzChek Elastase Assay Kit for elastase inhibitor screening, a peptide, chloromethyl ketone, can be used as a selective, collective inhibitor of elastase.

Oil Control Assay: Assays for determining a decrease in sebum secretion in a sebaceous gland and/or a decrease in sebum production in a sebaceous gland can be assayed using standard techniques known to those of skill in the art. In one embodiment, the forehead may be used. Each of the active ingredients disclosed herein, a combination of ingredients, or any one of compositions having such combinations for a defined period of time (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) , 11, 12, 13, 14, or longer) once or twice a day to one portion of the forehead, while the other portion of the forehead is not treated with the composition. After the predetermined period is over, the next skin secretion can be analyzed by applying excellent blotting paper to the treated and untreated forehead skin. This is done by first removing all sebum from the treated and untreated areas with a damp and dry cloth. A blotter may then be applied to the treated and untreated areas of the forehead, and an elastic band may already be placed around it to gently press the blotter over the skin. After 2 hours the blotter can be removed, allowed to dry, and then transilluminated with strong light. Dark blotting paper correlates with more sebum secretion (or light blotter correlates with decreased sebum secretion).

* * * * * * * * * * * * * *

All skin-active ingredients, compositions, or methods disclosed and claimed herein can be practiced and prepared without undue experimentation in light of the present disclosure. While the skin-active ingredients, compositions, or methods of the present invention have been described in terms of specific examples, those skilled in the art will appreciate that modifications will occur to the compounds, compositions, and/or methods and/or the concept, spirit and scope of the present invention. It will be apparent that the above method may be applied to a sequence or steps of the above method.

Claims (14)

Echinacea Purpuria purpurea ) extract, Silybum marianum extract and an effective amount of glycerin, comprising:
Wherein the composition activates human cannabinoid receptor type 2 in the skin, inhibits fatty acid amide hydrolase activity, and treats the skin. The topical skin care composition of claim 1 , wherein the composition further comprises water and sodium hyaluronate. According to claim 2, wherein the composition further comprises butylene glycol, glycereth-26, squalene, lecithin, glycine, tocopheryl acetate, xantam gum, hydroxyethylcellulose and phenoxyethanol, A topical skin care composition. The topical skin care composition of claim 1 , wherein the composition is a cream or lotion. The topical skin care composition of claim 1 , wherein the composition is an emulsion. 6. The topical skin care composition of claim 5, wherein the emulsion is an oil-in-water emulsion. According to claim 1, Echinacea Purpuria ( Echinacea ) purpurea ) The effective amount of the extract, 0.001 to 10% by weight of the composition, Silybum marianum ( Silybum marianum ) extract is 0.001 to 10% by weight of the composition, a topical skin care composition. The topical skin care composition of claim 1 , wherein the composition remains on the skin for at least 5 minutes after topical application. The topical skin care composition of claim 1 , wherein the composition is included in a mask. The topical skin care composition of claim 1 , wherein the skin is dry skin. The topical skin care composition of claim 1 , wherein the skin is erythematous skin. The composition of claim 1 , wherein the skin is facial skin. According to claim 1, Echinacea Purpuria ( Echinacea ) purpurea extract and Silybum marianum ) extract is an aqueous, alcoholic or aqueous-alcoholic extract, respectively. The topical skin care composition of claim 1 , wherein the composition further comprises a UV absorber, an antioxidant, a structurant, an emulsifier, a silicone containing compound, an essential oil, a thickener, or a preservative.